Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IONIS-AGT-LRx · ISIS 757456

Oligonucleotide (Antisense oligonucleotide) · Gene silencing: angiotensinogen (AGT) · developed by IONIS PHARMACEUTICALS

Phase 2 Most advanced trial (none active)
IONS Developer
1 Registered trials

What is IONIS-AGT-LRx?

IONIS-AGT-LRx is an antisense oligonucleotide that reduces angiotensinogen (AGT) production. It is administered by subcutaneous injection and is being studied in hypertension.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ISIS 757456
Drug type
Oligonucleotide (Antisense oligonucleotide)
Targets
angiotensinogen (AGT)
Mechanism
Gene silencing: angiotensinogen (AGT)
Therapy area
Cardiovascular
Developer
IONIS PHARMACEUTICALS (IONS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04714320 Phase 2 Hypertension Completed IONS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hypertension

Other drugs acting on AGT

More from IONIS PHARMACEUTICALS

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IONS page.

Follow IONS, the company behind IONIS-AGT-LRx

See IONS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IONS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.